Apr 9 |
Sensei Biotherapeutics to Participate in Canaccord Genuity’s Horizons in Oncology Virtual Conference
|
Apr 4 |
Sensei Biotherapeutics Announces Nature Communications Publication Describing Mechanism of Action of SNS-101 Selectively Targeting the Active Form of VISTA within the Tumor Microenvironment
|
Mar 22 |
Sensei Biotherapeutics to Participate in the 3rd Annual VISTA Symposium
|
Mar 6 |
Sensei Biotherapeutics to Present New Preclinical Data at Upcoming Scientific Conferences
|
Feb 28 |
Sensei Biotherapeutics reports FY results
|
Feb 28 |
Sensei Biotherapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights
|
Feb 7 |
Sensei Biotherapeutics to Present at Upcoming Conferences
|
Jan 4 |
Sensei Biotherapeutics Provides Corporate Update and Highlights Key Upcoming Milestones
|
Nov 3 |
Sensei Biotherapeutics Reports Favorable Clinical Data for SNS-101 at 2023 SITC Annual Meeting
|
Nov 1 |
Sensei Biotherapeutics Appoints Stephanie Krebs, MS, MBA, as Chief Business Officer
|